Kesimpta (Ofatumumab) is indicated for the treatment of:
a. Hypertension
b. Gout
c. Multiple sclerosis
d. Type II diabetes
e. Parkinsonism
Kesimpta (Ofatumumab) is indicated for the treatment of:
a. Hypertension
b. Gout
c. Multiple sclerosis
d. Type II diabetes
e. Parkinsonism
The active ingredient found in Kesimpta is Ofatumumab. It is available in a single-dose prefilled syringe.
Kesimpta (Ofatumumab) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
The precise mechanism by which Ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Hepatitis B virus (HBV) and quantitative serum immunoglobulins screening are required before the first dose.
Initial Dosing: 20 mg subcutaneously administered at Week 0, 1, and 2.
Respiratory tract infection, headache, injection-related reactions, and local injection site reactions are reported side effects of drug.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.
Which of the following statements is/are TRUE ABOUT Winlevi? [Select ALL THAT APPLY].
a. The active ingredient is Clascoterone.
b. It is an estrogen receptor inhibitor.
c. Indicated for the treatment of acne vulgaris.
d. It should only be used in patients 12 years of age or younger.
e. It is available as topical gel.
Which of the following statements is/are TRUE ABOUT Winlevi? [Select ALL THAT APPLY].
a. The active ingredient is Clascoterone.
b. It is an estrogen receptor inhibitor.
c. Indicated for the treatment of acne vulgaris.
d. It should only be used in patients 12 years of age or younger.
e. It is available as topical gel.
Answer: (a,c).
The active ingredient found in Winlevi is Clascoterone. It is available as cream. Each gram of Winlevi cream contains 10 mg of Clascoterone. It is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Erythema/reddening, pruritus, scaling/dryness, edema, stinging, and burning are commonly reported side effects of Winlevi.
Clascoterone is first-in-class topical androgen receptor inhibitor that tackles the androgen hormone component of acne in both males and females. Androgen receptor inhibitors act by limiting the effects of these hormones on increasing sebum production and inflammation.
Acne is a multifactorial skin condition, affected by four distinct pathways: excess oil (sebum) production, clogged pores (hyperkeratinization), bacteria growth (C. acnes), and inflammation. Topical treatment options that target androgens, which largely drive sebum production and inflammation, presented a significant unmet need in the acne treatment market until now.
Elevated potassium levels (Hyperkalemia) were observed in some patients during the clinical trials.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.
What is the principal advantage of Olinvyk, a newly approved opioid pain reliever, over available other opioid analgesics?
a. Cheap
b. Less chance of abuse
c. no dosage adjustments in patients with renal impairment
d. does not cause fatal respiratory depression
e. more patient compliance due to its oral dosage form
What is the principal advantage of Olinvyk, a newly approved opioid pain reliever, over available other opioid analgesics?
a. Cheap
b. Less chance of abuse
c. no dosage adjustments in patients with renal impairment
d. does not cause fatal respiratory depression
e. more patient compliance due to its oral dosage form
Answer: (c). Olinvyk is an opioid agonist that is the first new chemical entity in this IV drug class in decades and offers a differentiated profile that addresses a significant unmet need in the acute pain management landscape. Olinvyk delivers IV opioid efficacy with a rapid 2-5 minute onset of action. In addition, Olinvyk requires no dosage adjustments in patients with renal impairment, a large patient population with significant medical complications.
"Complex patients present unique challenges in the management of their postoperative acute pain, due to the presence of medical comorbidities that can complicate dosing," said Gregory Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University. "Olinvyk represents a new alternative for clinicians, due to its rapid onset of action, effective pain relief, and unique profile."
The active ingredient found in Olinvyk is Oliceridine. It is available in injection dosage form. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Olinvyk for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
1. Have not been tolerated, or are not expected to be tolerated
2. Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
The cumulative total daily dose should not exceed 27 mg.
Dosage Administration:
1. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
2. Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.
3. Initiate treatment with a 1.5 mg dose.
4. For patient controlled analgesia (PCA), recommended demand dose is 0.35 mg, with a 6-minute lock-out. A demand dose of 0.5 mg may be considered.
Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation or following a dose increase.
Concomitant use of Olinvyk with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Concomitant use with Serotonergic Drugs may result in serotonin syndrome. Discontinue Olinvyk if serotonin syndrome is suspected.
Nausea, vomiting, dizziness, headache and hypotension are reported side effects of the drug.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.
Who developed a Pharmacy Toolkit to help pharmacists engage and educate patients about the safe use, storage, and disposal of pain medicines?
a. CDC
b. CMSA
c. ASHP
d. AAOA
e. FTC
Answer: (d), In collaboration with its pharmacy partners and several state pharmacy associations, Allied Against Opioid Abuse (AAOA) developed a Pharmacy Toolkit to help pharmacists engage and educate patients about the safe use, storage, and disposal of pain medicines.
The AAOA Pharmacy Toolkit includes resources to help pharmacists raise awareness among patients about their rights, risks, and responsibilities associated with prescription opioids.
These resources include: a pharmacy display, patient handout, patient engagement guide, tips for talking with patients and caregivers, prescriber engagement guide, safe storage and disposal training, and social graphics.
To learn more about the Pharmacy Toolkit, please visit:
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.
The FDA has recently approved Xywav for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. Another drug Xyrem is available for the same indication in the US. What is a principal advantage of using Xywav over Xyrem?
a. Less side effects
b. Less potential for abuse
c. Low sodium contents
d. More potency
e. Cheaper
The FDA has recently approved Xywav for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. Another drug Xyrem is available for the same indication in the US. What is a principal advantage of using Xywav over Xyrem?
a. Less side effects
b. Less potential for abuse
c. Low sodium contents
d. More potency
e. Cheaper
Answer: C
The active ingredients found in Xywav is (calcium, magnesium, potassium, and sodium oxybates) oral solution. It is for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium - or approximately 1,000 to 1,500 mg/night - than sodium oxybate at the recommended dosage range of 6 to 9 grams.
Multiple Xywav dosing options are available for adult and pediatric patients. Prescribers can titrate Xywav into unequal doses taken over the course of the night. When patients start Xywav after sodium oxybate, Xywav treatment is initiated at the same dose and regimen as sodium oxybate (gram for gram) and titrated as needed based on efficacy and tolerability.
Xywav makes it possible for patients to have a lower-sodium oxybate treatment option. This may help patients taking sodium oxybate better align with daily sodium intake recommendations including those by the American Heart Association. Excess sodium intake has been linked with increases in blood pressure, hypertension, stroke, and other cardiovascular disease.
Xyrem (Sodium oxybate) carries warnings about its high sodium content,10 and was previously the only product approved to treat both cataplexy and EDS in patients with narcolepsy 7 years of age and older and designated as a standard of care for the treatment of cataplexy and EDS by the American Academy of Sleep Medicine.
Xywav has a Boxed Warning as a central nervous system depressant, and for its potential for abuse and misuse. Because of the risks of CNS depression and abuse and misuse, Xywav is available only through a restricted program under a REMS called the Xywav and Xyrem REMS Program.
Most common adverse reactions in adults are headache, nausea, dizziness, decreased appetite, parasomnia, diarrhea, hyperhidrosis, anxiety and vomiting.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question does not show up in an MPJE. We are just posting to mpje group for your knowledge.
a. Hypertension
b. Heart failure
c. Depression
d. Type II diabetes mellitus
e. Panic disorder
Entresto is indicated for the treatment of:
a. Hypertension
b. Heart failure
c. Depression
d. Type II diabetes mellitus
e. Panic disorder
Answer: b. The active ingredients found in Entresto are Sacubitril and Valsartan. Sacubitril is a neprilysin inhibitor whereas Valsartan is an angiotensin II receptor blocker.
It is available as tablets (24/26 mg, 49/51 mg and 97/103 mg).
It is indicated:
1. to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
2. for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
Hypotension, hyperkalemia, cough, dizziness and renal failure are reported side effects of the drug.
The Multistate Pharmacy Jurisprudence Examination (MPJE) is a standardized exam that tests pharmacy law knowledge for licensure across various states, including Alaska. Preparing for the Alaska MPJE requires understanding both federal and state-specific laws that govern pharmacy practices. This guide aims to provide a concise overview of what to expect and how to prepare for the Alaska MPJE. We will cover following topics. Also you can find more details and exam preparation material here.
The Alaska MPJE is designed to assess a candidate's knowledge of pharmacy laws and regulations specific to the state of Alaska, as well as federal pharmacy laws. It is developed by the National Association of Boards of Pharmacy (NABP) and is a requirement for those seeking pharmacist licensure in Alaska.
The Alaska Board of Pharmacy uses this exam to ensure that pharmacists have a comprehensive understanding of the legal aspects of pharmacy practice in the state, including controlled substances, prescription requirements, and licensure regulations.
2. Exam Format and Content
The MPJE consists of 120 questions, of which 100 are scored. The remaining 20 are pretest questions and do not affect the final score. The test is computerized and includes various question formats, such as multiple-choice, multiple-response, ordered response, and constructed response.
The exam covers three primary content areas:
Pharmacy Practice (83%): This section focuses on the practice of pharmacy in different settings. It includes questions about the legal requirements for drug distribution, record-keeping, and patient counseling.
Licensure, Registration, Certification, and Operational Requirements (15%): Questions in this area relate to the qualifications and legal requirements for obtaining and maintaining a pharmacist's license, registration, and other certifications in Alaska.
General Regulatory Processes (2%): This section covers federal laws and regulations, including those related to controlled substances and the Drug Enforcement Administration (DEA).
Candidates have 2.5 hours to complete the exam. The minimum passing score is 75.
3. Preparing for the Exam
Preparation is key to successfully passing the Alaska MPJE. Here are some steps to help you get started:
Understand Alaska Pharmacy Laws: Since the exam is state-specific, review Alaska's pharmacy laws and regulations, including rules from the Alaska Board of Pharmacy. Pay special attention to areas such as the Alaska Pharmacy Act and controlled substance regulations.
Review Federal Pharmacy Laws: Although the focus is on Alaska-specific regulations, federal laws such as the Controlled Substances Act (CSA) and the Food, Drug, and Cosmetic Act (FDCA) are also covered.
Outline Key Areas: Focus on areas like prescription regulations, labeling requirements, pharmacy operations, drug schedules, pharmacist responsibilities, and security measures for controlled substances.
Create a Study Schedule: Set aside regular study time each day or week leading up to the exam. Break down the material into manageable sections to cover all necessary content.
4. Study Resources
You can find plenty of resources to prepare for your ALASKA MPJE exam on PharmacyExam.
For more details visit this page.
The Multistate Pharmacy Jurisprudence Examination (MPJE) is a crucial step for pharmacists seeking licensure in the United States. Administered by the National Association of Boards of Pharmacy (NABP), the MPJE tests a candidate's knowledge of federal and state-specific laws governing the practice of pharmacy. This exam ensures that pharmacists are well-versed in legal and ethical guidelines, which is essential for safe and effective practice. This article provides an in-depth look at the MPJE, including its applicability, format, and tips for preparation.
The MPJE is required for pharmacy licensure in most U.S. states and jurisdictions. Specifically, 48 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands mandate the MPJE for licensure. However, there are exceptions:
Exceptions: Currently, the MPJE is not required in Arkansas and California. These states have their own state-specific jurisprudence exams.
Pharmacists who plan to practice in multiple states must take the MPJE for each state, as the exam includes state-specific questions alongside federal law questions.
Exam Format
The MPJE is designed to assess the candidate's knowledge in three main areas:
Pharmacy Practice (83% of the exam): This section focuses on the application of laws and regulations in pharmacy practice, including the distribution and dispensing of medications, patient care, and the management of pharmacy operations.
Licensure, Registration, Certification, and Operational Requirements (15% of the exam): This section covers the requirements for becoming licensed as a pharmacist, including the procedures for obtaining and maintaining licensure, as well as the operational requirements for running a pharmacy.
General Regulatory Processes (2% of the exam): This smaller section deals with the overall framework of regulatory processes, including how laws and regulations are developed, implemented, and enforced.
The MPJE consists of 120 questions, of which 100 are scored, and 20 are pretest questions that do not count towards the final score. Candidates have 2 hours and 30 minutes to complete the exam.
The MPJE uses a scaled scoring system, with scores ranging from 0 to 100. To pass, candidates typically need to achieve a minimum scaled score of 75. This score does not directly reflect the number of correct answers but rather the difficulty of the questions answered correctly.
Please be aware of the scam, originally brought to our attention by one of our customer. This company website URL is rx-exam.com. The website phone number is 123-456-7890 - which itself suggests it is a fraud. They are claiming to sell materials from their websites for various pharmacy related exams. All materials are offered for online purchase. Many customers have lost their money since after purchasing using credit cards; they don't receive any material.
Please DO NOT PURCHASE any material from this site www.rx-exam.com.
PharmacyExam (RxExam) is not affiliated with this company and bears no responsibility for any financial loss. Please pass this message to your friends. The authenticated web site for our company is www.pharmacyexam.com
Thank you.
Founder and President
Manan Shroff
WARNING!
Please be aware of the scam, originally brought to our attention by one of our customer.This company website URL is rx-exam.com. The website phone number is 123-456-7890 - which itself suggests it is a fraud.They are claiming to sell materials from their websites for various pharmacy related exams. All materials are offered for online purchase. Many customers have lost their money since after purchasing using credit cards; they don't receive any material.
PleaseDO NOT PURCHASEany material from this sitewww.rx-exam.com.
PharmacyExam (RxExam) is not affiliated with this company and bears no responsibility for any financial loss. Please pass this message to your friends. The authenticated web site for our company iswww.pharmacyexam.com
